Agostini, Antonio
 Distribuzione geografica
Continente #
EU - Europa 153
AS - Asia 98
NA - Nord America 87
SA - Sud America 26
Totale 364
Nazione #
US - Stati Uniti d'America 86
IT - Italia 58
CN - Cina 32
SG - Singapore 26
BR - Brasile 22
DE - Germania 20
SE - Svezia 19
IN - India 17
FR - Francia 14
FI - Finlandia 9
GB - Regno Unito 8
IE - Irlanda 8
ID - Indonesia 7
NL - Olanda 5
KR - Corea 4
RU - Federazione Russa 4
AT - Austria 3
CH - Svizzera 3
BD - Bangladesh 2
HK - Hong Kong 2
TR - Turchia 2
TW - Taiwan 2
AR - Argentina 1
BE - Belgio 1
CA - Canada 1
CL - Cile 1
CO - Colombia 1
GE - Georgia 1
JO - Giordania 1
PL - Polonia 1
TM - Turkmenistan 1
VE - Venezuela 1
VN - Vietnam 1
Totale 364
Città #
Singapore 20
Chandler 19
Rome 19
Hyderabad 14
Ashburn 12
Milan 11
Jakarta 7
Dublin 5
Hefei 5
Helsinki 5
Nuremberg 5
Beijing 4
Boardman 4
Cattolica 4
Marseille 4
Seoul 4
Chions 3
Council Bluffs 3
Düsseldorf 3
Frankfurt am Main 3
The Dalles 3
Verona 3
Agno 2
Belo Horizonte 2
Falkenstein 2
Florence 2
Guwahati 2
Hong Kong 2
Lappeenranta 2
Lauterbourg 2
London 2
Los Angeles 2
Munich 2
Princeton 2
Vienna 2
Amman 1
Ankara 1
Aracaju 1
Araruama 1
Araxá 1
Ashgabat 1
Atlanta 1
Augusta 1
Bern 1
Bogotá 1
Bom Despacho 1
Boston 1
Bremen 1
Brussels 1
Cajamar 1
Campinas 1
Canoinhas 1
Caracas 1
Chennai 1
Chicago 1
Chiswick 1
Conceição do Coité 1
Coronel Fabriciano 1
Curitiba 1
Dhaka 1
Fairfield 1
Hanoi 1
Hortolândia 1
Hounslow 1
Houston 1
Hsinchu 1
Istanbul 1
Juiz de Fora 1
Moscow 1
Mountain View 1
New Bedfont 1
Newark 1
North Bergen 1
Ottawa 1
Paraisópolis 1
Paris 1
Passa Quatro 1
Portsmouth 1
Redmond 1
Sacramento 1
Salerno 1
Salvador 1
San Fernando 1
Santa Bárbara d'Oeste 1
Seattle 1
Serra 1
Shantou 1
St Petersburg 1
Stockholm 1
São João del Rei 1
São Vicente 1
Taipei 1
Tbilisi 1
Trieste 1
Ulianópolis 1
Warsaw 1
Washington 1
Wilmington 1
Woodbridge 1
Zhengzhou 1
Totale 251
Nome #
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer 98
CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer 61
Identification of spatially-resolved markers of malignant transformation in Intraductal Papillary Mucinous Neoplasms 61
Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms of Treatment Response 59
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer 46
KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy 26
Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers 24
Totale 375
Categoria #
all - tutte 2.583
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.583


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202231 0 0 0 0 7 3 4 3 3 1 5 5
2022/202372 10 11 4 8 2 7 6 2 9 0 3 10
2023/202479 0 9 4 2 7 6 13 0 1 13 5 19
2024/2025193 5 0 16 6 14 14 17 10 27 32 48 4
Totale 375